Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
International Journal of Chronic Obstructive Pulmonary Disease|August 8, 2022
Disease Progression and Age as Factors Underlying Multimorbidity in Patients with COPD: Results from COSYCONETPeter Alter, Kathrin Kahnert, Franziska C Trudzinski, et al.
Cancers|August 23, 2020
C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center StudyJakob M Riedl, Dominik A Barth, Wolfgang M Brueckl, et al.
The Lancet. Rheumatology|April 4, 2022
Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trialMeiLan K Han, Martti Antila, Joachim H Ficker, et al.
Respiration; International Review of Thoracic Diseases|March 3, 2026
Treatment outcomes of endoscopic lung volume reduction with valves in advanced lung emphysema patients are largely independent of body mass index: Data from the German Lung Emphyema RegistryJacopo Saccomanno, Thomas Sgarbossa, Konrad Neumann, et al.
Patient Preference and Adherence|December 9, 2024
Association of Patients' Knowledge on the Disease and Its Management with Indicators of Disease Severity and Individual Characteristics in Patients with Chronic Obstructive Pulmonary Disease (COPD): Results from COSYCONET 2Carolina Fischer, Maria Siakavara, Peter Alter, et al.
The Lancet. Respiratory Medicine|April 2, 2021
Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trialJürgen Behr, Antje Prasse, Michael Kreuter, et al.
The Lancet. Respiratory Medicine|December 6, 2016
Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE)Noel G McElvaney, Jonathan Burdon, Mark Holmes, et al.
Thrombosis and Haemostasis|December 7, 2017
Dabigatran after Short Heparin Anticoagulation for Acute Intermediate-Risk Pulmonary Embolism: Rationale and Design of the Single-Arm PEITHO-2 StudyFrederikus A Klok, Walter Ageno, Stefano Barco, et al.
European Heart Journal|May 24, 2019
Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trialStefano Barco, Irene Schmidtmann, Walter Ageno, et al.
The European Respiratory Journal|August 30, 2020
Survival and quality of life after early discharge in low-risk pulmonary embolismStefano Barco, Irene Schmidtmann, Walter Ageno, et al.
Pageof 6